is an immunosuppressant drug used to prevent rejection in organ transplantation and neointimal hyperplasia when delivered from drug-eluting stents. Major side effects of SRL include edema and local collection of intimal lipid deposits at drug-eluting stent sites, suggesting that SRL impairs endothelial barrier function (EBF). The aim of this study was to address the role of SRL on impaired EBF and the potential mechanisms involved. Approach and Results-Cultured human aortic endothelial cells (HAECs) and intact human and mouse endothelium was examined to determine the effect of SRL, which binds FKBP12.6 to inhibit the mammalian target of rapamycin, on EBF. EBF, measured by transendothelial electrical resistance, was impaired in HAECs when treated with SRL or small interfering RNA for FKBP12.6 and reversed when pretreated with ryanodine, a stabilizer of ryanodine receptor 2 intracellular calcium release channels. Intracellular calcium increased in HAECs treated with SRL and normalized with ryanodine pretreatment. SRL-treated HAECs demonstrated increases in protein kinase C-α phosphorylation, a calcium sensitive serine/threonine kinase important in vascular endothelial (VE) cadherin barrier function through its interaction with p120-catenin (p120). Immunostaining of HAECs, human coronary and mouse aortic endothelium treated with SRL showed disruption of p120-VE cadherin interaction treated with SRL. SRL impairment of HAEC EBF was reduced with protein kinase C-α small interfering RNA. Mice treated with SRL demonstrated increased vascular permeability by Evans blue albumin extravasation in the lungs, heart, and aorta. Conclusions-SRL-FKBP12.6 impairs EBF by activation of protein kinase C-α and downstream disruption of the p120-VE cadherin interaction in vascular endothelium. These data suggest this mechanism may be an important contributor of SRL side effects related to impaired EBF. (Arterioscler Thromb Vasc Biol. 2013;33:2425-2431.) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
E ndothelial barrier function (EBF) is required for vascular homeostasis, whereas its dysfunction can lead to pathological conditions, such as atherosclerosis and edema. 1, 2 Sirolimus (SRL) is a mammalian target of rapamycin (mTOR) inhibitor used to prevent organ transplantation rejection and restenosis after percutaneous coronary intervention when delivered from drug-eluting stents. The predominant side effect of systemic SRL use is edema while local elution with drug-eluting stents can result in collections of foamy macrophages within the neointima (termed neoatherosclerosis) contributing to late thrombotic events. [3] [4] [5] These side effects limit the therapeutic use of SRL and suggest that the drug, when given both systemically and locally, impairs EBF. Although the major therapeutic mechanism of SRL is through mTOR inhibition, it is not clear whether mTOR inhibition itself leads to increased vascular permeability. 6, 7 Therefore, understanding the underlying mechanisms by which SRL impairs EBF may clarify whether these effects are directly related to mTOR inhibition or may represent offtarget effects of SRL.
SRL inhibits mTOR through specific binding of the FKBP12, a ubiquitous, cytosolic 12-KD FK506-binding protein and key stabilizing component of ryanodine (RyR2) intracellular calcium release channels in various cell types. 8, 9 SRL has subnanomolar affinity to FKBP12 with 50% inhibitory concentration for the mTOR signaling pathway at this subnanomolar dose range. 10, 11 In addition, systemic use of SRL can lead to alteration of vascular intracellular calcium levels via displacement of the FKBP12.6, a vasculature specific isoform, 12 resulting in decreased endothelial-dependent relaxation responses via protein kinase C (PKC) activation through a calcium-dependent mechanism. 8, 13 The α isoform of PKC (PKCα) is a calcium sensitive threonine/serine kinase whose activation plays an important role in increasing vascular permeability, both through calcium-dependent and independent mechanisms. [14] [15] [16] [17] Studies suggest that PKCα activation leads to p120-catenin (p120) dissociation from vascular endothelial (VE) cadherin, resulting in loss of VE cadherin homotypic interaction at the adherens junction, VE cadherin degradation, and impaired EBF. 18, 19 In this study, we hypothesized that SRL-FKBP12.6 interaction would impair EBF by increasing intracellular calcium via RyR2 destabilization and activation of PKCα leading to disruption of p120-VE cadherin interaction. To test this, we used human aortic endothelial cells (HAECs) to measure PKCα phosphorylation and the association of p120 and VE cadherin with and without SRL treatment. Additionally, we measured EBF in HAECs with transendothelial electrical resistance in addition to intracellular calcium levels under both the influence of SRL and pharmacological RyR2 stabilization with ryanodine. Furthermore, small interfering RNAs (siRNAs) for FKBP12.6, PKCα, and selective mTOR inhibition with an ATP-competitive inhibitor, torin2, 20 were used to determine their respective mechanistic roles. Finally, vascular permeability was measured in a C57BL/6 mouse model after SRL treatment in addition to immunostaining for p120-VE cadherin in intact mouse aortic and human coronary endothelium after SRL treatment.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

SRL Activates PKCα and Alters the Interaction of p120-Catenin With PKCα and VE Cadherin
VE cadherin interacts with p120 to maintain EBF by repressing signals for VE cadherin endocytosis and degradation. 2, 18 Activation of PKCα, a serine/threonine kinase, is involved destabilizing p120-VE cadherin interactions. 18 When HAECs were treated with SRL, activation of PKCα occurred at all doses tested (ie, 1-500 nmol/L; Figure 1A ). PKCα activation was also seen as quickly as 30 minutes after SRL treatment and remained activated at 24 hours ( Figure 1B ). The interaction of p120 with phosphorylated PKCα and VE cadherin in SRL-treated HAECs was examined using immunoprecipitation for p120. The interaction of p120 with phosphorylated PKCα significantly increased after 30 minutes, whereas its interaction with VE cadherin significantly decreased during this period ( Figure 1C and 1D ). This suggests that SRL activates PKCα in HAECs, which is associated with a sustained increase in phosphorylated PKCα-p120 but a decrease in p120-VE cadherin interaction.
SRL Treatment Mobilizes p120 From the Membrane to the Cytosol and Increases Interendothelial Gap Area
To confirm these observations, we next examined the interaction of p120 and VE cadherin by immunostaining in HAECs treated with SRL. SRL treatment at 24 hours increased p120 (red) mobilization from the HAEC membrane to the cytosol when compared with no treatment ( Figure 1E ). In addition, we observed evidence of intracellular deposits with increased p120-VE cadherin staining suggestive of membrane disruption (white arrow, Figure 1E ). There was a significant decrease in colocalization of p120 and VE cadherin as measured by Pearson correlation coefficient ( Figure 1F ). At 24 hours, there was decrease in overall protein expression of VE cadherin ( Figure 1G ). Additionally, the interendothelial gap areas measured by VE cadherin immunostaining remained increased up to 72 hours ( Figure 1H ), suggesting disruption of endothelial barrier. Similar to SRL treatment, removal of FKBP12.6 via siRNA showed p120-VE cadherin disruption compared with nontargeting siRNA (Scr) with immunostaining and an increase in phosphorylated PKCα-p120 interaction but a decrease in p120-VE cadherin interaction using immunoprecipitation with p120 ( Figure IA -IC in the online-only Data Supplement).
SRL Treatment or FKBP12.6 Knockdown But Not Selective mTOR inhibition Impairs EBF in a PKCα−Dependent Manner
SRL treatment or removal of FKBP12.6, a FK506-binding protein that normally binds RyR2 in the vasculature, 12 with siRNA impaired HAEC EBF with significant reduction in normalized transendothelial electrical resistance, respectively, during the measured period ( Table I in the online-only Data Supplement). This impairment was reversed when HAECs were pretreated with ryanodine (ryan), a stabilizer of RyR2 calcium release channels ( Figure 2C ). There was an initial rise in transendothelial electrical resistance with the control and ryanodine-treated groups, suggesting an initial barrier stabilizing effect that was seen not in the treated groups ( Figure 2B and 2C). SRL impairment of HAEC EBF was also attenuated when PKCα was removed via siRNA ( Figure 2A and 2B), suggesting PKCα is required for this effect. Transwell permeability of HAEC monolayers was also increased with SRL treatment and improved when pretreated with ryanodine ( Figure 2D ; Table II in the online-only Data Supplement). In HAECs, we observed a significant increase in intracellular calcium content after SRL treatment up to 24 hours ( Figure 2F and 2G). Pretreatment with ryanodine ameliorated the initial increase in intracellular calcium levels up to 30 minutes ( Figure 2F and 2G). Torin2, a selective ATP-competitive inhibitor of the mTOR that does not bind FKBP12/12.6, 21 did not impair EBF while inhibiting the downstream targets of mTOR signaling pathway and endothelial proliferation similar to SRL 22 ( Figure 2G and 2H; Figure IIA and IIB in the onlineonly Data Supplement). Collectively, these results suggest that displacement of FKBP12.6 from RyR2 calcium release channels by SRL, rather than mTOR inhibition, induces an endothelial intracellular calcium leak and increases PKCα phosphorylation leading to impaired EBF.
SRL Treatment Increased Vascular Permeability by Disrupting the p120-VE Cadherin Interaction
We examined the effect of SRL treatment EBF in adult male C57BL/6 mice (1 mg/kg per day intraperitoneal for 3 days). Dosing was based on previous experimental data to achieve steady-state clinical drug levels without significant immune suppression 7,23,24 SRL treatment qualitatively increased Evans blue albumin extravasation in the myocardium both in the microvascular and macrovascular beds as seen using CD31 staining ( Figure 3A ) in addition to significantly increasing Evans blue albumin extravasation in homogenates of the myocardial, aortic, and pulmonary tissue ( Figure 3B ). In addition, in mouse aortas, there was an increase in both p120 (red) and VE cadherin (green) mobilization from the membrane into the cytosol when compared with vehicle-treated mice, resulting in decreased colocalization of these proteins ( Figure 3C ; Figure  IIIA 
Discussion
This study is the first to propose a novel mechanism by which SRL-FKBP12.6 impairs EBF independent of the mTOR signaling pathway ( Figure 4A-4C ). We show evidence that pharmacologically displacing FKBP12.6 with SRL in vascular endothelial cells leads to calcium-dependent activation of PKCα, disruption of the p120-VE cadherin interaction, and impaired EBF. We suggest that this mechanism involves destabilization of the RyR2 intracellular calcium release channels by FKBP12.6 displacement, leading to increased intracellular calcium and found impaired EBF to be improved through RyR2 stabilization with ryanodine. These findings were recapitulated through removal of FKBP12.6 via siRNA again, showing disruption of the p120-VE cadherin interaction and impaired EBF. Furthermore, removal of PKCα via siRNA abrogates the effect of SRL on EBF. Additionally, we observed that a selective ATP-competitive mTOR inhibitor, which does not require FKBP12/12.6 binding, 20,21 did not affect EBF, suggesting that SRL-induced impairment of EBF is unrelated to mTOR inhibition. Finally, we show increased vascular permeability with SRL-treated mice in different vascular beds and disruption of p120-VE cadherin 6, 7, 25, 26 Downstream effectors of the mTOR signaling pathway, such as Akt/protein kinase B, a serine/threonine kinase, and downstream effector of mTOR complex 2, have been proposed to regulate endothelial permeability; however, results differ. 6, 7, [25] [26] [27] VE cadherin content, however, are consistently decreased by SRL treatment, suggesting the SRL may affect VE cadherin content and vascular endothelial homeostasis regardless of the model used. 6, 7, 25 Studies suggest that p120-catenin interaction with VE cadherin may act as a set point for endothelial homeostasis and cellular VE cadherin content. 28 PKC, a family of serine/threonine kinases, and its α isoform are key regulators of endothelial function both in the macrovasculature and microvasculature 29 and has been shown to modulate EBF through disruption of the p120-VE cadherin interaction in addition to affecting endothelial cytoskeleton dynamics by activating myosin light chain-2 through myosin light chain kinase. 18, 30, 31 Our study suggests that the effects of SRL on EBF are mediated through alteration of p120-VE cadherin interaction and likely disruption of vascular homeostasis in multiple vascular beds ( Figure 3A and 3B) . 8, 18, 29 Although we do not see any Figure 1H ). 31, 32 In vivo, p120-VE cadherin disruption and increased vascular permeability were observed in different vascular beds in C57BL/6 mice treated with SRL (1 mg/kg per day for 3 days) compared with vehicle-treated control. This dose was chosen to achieve steady-state clinical drug levels and suppression of mTOR signaling products without significant immune suppression. 7, 23, 24 In the mouse aortic endothelium, there is decreased p120-VE cadherin colocalization within the membrane in the treated animals. Finally, we observed a similar disruption in p120-VE cadherin interaction within a human coronary endothelium treated ex vivo with SRL (500 nmol/L for 24 hours), suggesting that this effect not only occurs in intact human endothelium but also has an acute time course (<24 hours). This is consistent with our proposed mechanism as opposed to one that involves mTOR/Akt inhibition, which requires longer treatment duration. 33 
Clinical Implications
SRL is an immunosuppressant with diverse systemic and local effects. Its main therapeutic mechanism is through the allosteric inhibition of mTOR by SRL-FKBP12 complex similar to the inhibition of calcineurin by the FK506-FKBP12 complex. 34 Interestingly, although SRL and its analogs (ie, everolimus) have gained increasing use over calcineurin-inhibitors, such as FK506 (ie, tacrolimus), in the prevention of solid organ transplant rejection, edema represents the most common adverse reaction in both classes of medications. 3, 35 In a retrospective registry of heart transplant recipients, edema was the most frequent cause for discontinuation of mTOR inhibitors. 3 Additionally, when comparing SRL with newer analogs, such as everolimus, a 40-O-hydroxyethyl-derivative of SRL, increased tolerability to everolimus with respect to edema has been shown. 36 This is likely because of the overall decreased affinity of everolimus to FKBP12/12.6 compared with SRL. 11 These clinical findings suggest that edema is related to systemic inhibition of endothelial FKBP12.6. Additionally, up to one third of coronary stents that elute mTOR inhibitors have evidence of intimal lipid deposits within the stent, 4, 5 This also implies that SRL analogs, such as everolimus, which have reduced affinity to FKBP12/12.6 may also likely have reduced local adverse effects compared with SRL; however, this has not yet been studied. 11 A role for specific mTOR inhibitors, such as ATP-competitive mTOR inhibitors, as therapeutic options for local elution in drug-eluting stents, however, should be considered. 20
Conclusions
SRL-FKBP12.6 impairs EBF by PKCα activation and disruption of the p120-VE cadherin interaction in the vascular endothelium. This mechanism may be an important contributor of SRL side effects related to impaired EBF. Figure 4 . Proposed mechanism of sirolimus (SRL) to impair endothelial barrier function. A, SRL displaces FKBP12.6 from ryanodine receptor 2 (RyR2) calcium release channel (blue oval) in vascular endothelial cells, resulting in increased intracellular release of free Ca 2+ from the endoplasmic reticulum. B, Protein kinase C-α (PKCα) is activated and it destabilizes the p120-VE cadherin interaction. C, p120 and eventually VE cadherin move from the membrane to the intracellular space leading to impaired endothelial barrier function.
